Previously we showed that a recombinant humanized monoclonal antibody (scFv) to CEACAM6 induced apoptosis by PARP cleavage in cell culture, inhibited of cell proliferation via disruption of anchorage independence and anti-tumor activity in a mouse xenograft model of PDA alone and synergistically with gemcitabine10. The gene discussed is CEACAM6; the disease is Patent ductus arteriosus.